var docs;if (!docs) docs =[]; docs["93"]={"9300":"<p><b>Title</b> Telithromycin / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of telithromycin and ketoconazole.</p> \n<p><b>Discussion</b> In a clinical study summarized in telithromycin US prescribing information, coadministration of ketoconazole increased the maximum concentration (Cmax) and AUC of telithromycin by 51% and 95%, respectively.<sup>2</sup> Coadministration of ketoconazole (400 mg orally daily for 5 days) in patients 60 years old or older with renal impairment (estimated creatinine clearance 30 to 80 mL/min) increased the Cmax and AUC of telithromycin (800 mg orally daily for 5 days) to 1.6 and 2.7 times, respectively, values in healthy subjects not given ketoconazole.<sup>3</sup> Telithromycin Cmax and AUC were 4- to 5-fold higher in 2 ketoconazole-treated patients with more severe renal impairment (estimated creatinine clearance less than 30 mL/min) than in healthy subjects not given ketoconazole.<sup>1,2</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4-mediated telithromycin metabolism. Telithromycin inhibition of CYP3A4-mediated ketoconazole metabolism may also theoretically increase ketoconazole exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2015.</p>\n<p>2. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. <i>Int J Clin Pharmacol Ther</i>. 2005;43(3):123-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15792396\">[PubMed 15792396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9301":"<p><b>Title</b> Telithromycin / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of telithromycin and itraconazole. Itraconazole US labeling states that its use with telithromycin is contraindicated in patients with severe renal or hepatic impairment.</p> \n<p><b>Discussion</b> In a clinical study of 18 healthy volunteers, coadministration of itraconazole (200 mg orally daily for 14 days) increased the maximum concentration (Cmax) and AUC of telithromycin (800 mg orally daily for 4 days) by 22% and 54%, respectively.<sup>1,2</sup> In other clinical studies, coadministration of the closely-related azole antifungal agent ketoconazole increased the Cmax and AUC of telithromycin by 51% and 95%, respectively,<sup>2</sup> and coadministration of ketoconazole (400 mg orally daily for 5 days) in patients 60 years of age or older with renal impairment (estimated creatinine clearance 30 to 80 mL/min) increased the Cmax and AUC of telithromycin (800 mg orally daily for 5 days) to 1.6 and 2.7 times, respectively, values in healthy subjects not given ketoconazole.<sup>3</sup> Telithromycin Cmax and AUC were 4- to 5-fold higher in 2 ketoconazole-treated patients with more severe renal impairment (estimated creatinine clearance less than 30 mL/min) than in healthy subjects not given ketoconazole.<sup>2,3</sup><br><br>The suspected primary mechanism of this interaction is itraconazole inhibition of CYP3A4-mediated telithromycin metabolism. Telithromycin inhibition of CYP3A4-mediated itraconazole metabolism may also theoretically increase itraconazole exposure. Telithromycin labeling recommends avoiding its coadministration with itraconazole,<sup>2</sup> while itraconazole labeling states that coadministration is contraindicated in patients with severe renal or hepatic impairment.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. <i>Pharmacotherapy</i>. 2005;25(1):42-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767219\">[PubMed 15767219]</a></p>\n<p>2. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2015.</p>\n<p>3. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. <i>Int J Clin Pharmacol Ther</i>. 2005;43(3):123-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15792396\">[PubMed 15792396]</a></p>\n<p>4. Sporanox (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9302":"<p><b>Title</b> ChlorproPAMIDE / Urinary Acidifying Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased chlorpropamide effects (eg, hypoglycemia) if combined with a urinary acidifying agent.</p>\n<div>\n <p><b>Urinary Acidifying Agents Interacting Members</b> Ammonium Chloride, Methenamine, Piperazine, Potassium Phosphate, Sodium Acid Phosphate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, administration of chlorpropamide (250 mg single oral dose) during treatment with ammonium chloride (approximately 21 g over 64 hours to maintain urinary pH 4.7 to 5.5) resulted in a 41% and 38% increase in the chlorpropamide AUC and half-life, respectively.<sup>1</sup> The amount of chlorpropamide excreted unchanged in the urine decreased 93%.<sup>1</sup><br><br>The proposed mechanism of this interaction is that chlorpropamide exists in a more nonionized and reabsorbable form in an acidic environment. Thus, more drug is reabsorbed, leading to reduced urinary excretion and increased drug exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. <i>Clin Pharmacol Ther</i>. 1983;33(3):386-393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6297841\">[PubMed 6297841]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9303":"<p><b>Title</b> CefTAZidime / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may diminish the therapeutic effect of CefTAZidime. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.</p> \n<p><b>Discussion</b> A case report describes a 2.5-month-old infant diagnosed with <i>Salmonella enteritidis</i> meningitis.<sup>1</sup> He was started on chloramphenicol (100 mg/kg/day) and ceftazidime (100 mg/kg/day) but showed little to no improvement over the next 4 days, with persistently positive cerebral spinal fluid cultures. In vitro testing revealed that samples of the infant's serum and cerebrospinal fluid were unable to kill the organism despite concentrations of both drugs being well above the minimum inhibitory concentrations (MIC) and ceftazidime concentrations well above the minimum bactericidal concentration. Additional in vitro testing revealed that ceftazidime was bactericidal at the MIC, but if combined with chloramphenicol, was no longer bactericidal, and was only bacteriostatic at concentrations 30 times the MIC. Chloramphenicol therapy was discontinued and the infant recovered after 7 days of therapy with ceftazidime alone.<sup>1</sup> An additional study found antagonism between ceftazidime and chloramphenicol in vitro,<sup>2</sup> while another in vitro analysis failed to find antagonism between these agents.<sup>3</sup><br><br>Labeling for at least one ceftazidime product in the US and in Canada states that antagonism between chloramphenicol and ceftazidime has been reported in vitro, and antagonism in vivo may occur.<sup>4,5</sup> Due to this potential antagonism, particularly when bactericidal activity is desired, this drug combination should be avoided.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. French GL, Ling TK, Davies DP, Leung DT. Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis. <i>Br Med J (Clin Res Ed)</i>. 1985;291(6496):636-637. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3928061\">[PubMed 3928061]</a></p>\n<p>2. Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M. Use of the E test to assess synergy of antibiotic combinations against isolates of <i>Burkholderia cepacia</i>-complex from patients with cystic fibrosis. <i>Eur J Clin Microbiol Infect Dis</i>. 2003;22(1):28-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12582741\">[PubMed 12582741]</a></p>\n<p>3. Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of <i>Pseudomonas cepacia</i> from patients with cystic fibrosis. <i>Int J Antimicrob Agents</i>. 1993;3(3):205-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18611561\">[PubMed 18611561]</a></p>\n<p>4. Fortaz (ceftazidime) [prescribing information]. Cary, NC: Covis Pharmaceuticals Inc; August 2014.</p>\n<p>5. Fortaz (ceftazidime) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9304":"<p><b>Title</b> Zaleplon / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zalephon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the zaleplon prescribing information, administration of the strong CYP3A4 inducer rifampin (600 mg once daily for 14 days) decreased the zaleplon AUC and maximum serum concentration approximately 80%.<sup>1</sup><br><br>Zaleplon prescribing information states that coadministration with strong CYP3A4 inducers may result in reduced efficacy of zaleplon.<sup>1</sup> In patients who require treatment with strong CYP3A4 inducers, use of a hypnotic that is not metabolized by CYP3A4 instead of zaleplon should be considered.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9305":"<p><b>Title</b> Palifermin / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may increase the serum concentration of Palifermin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> If heparin is used to maintain an intravenous line, rinse the line with saline prior to and after palifermin administration. Monitor patients closely for evidence of palifermin-related toxicities.</p> \n<p><b>Discussion</b> One study of healthy subjects found that coadministration with a single IV bolus dose of palifermin 60 mcg/kg and therapeutic levels of unfractionated heparin resulted in an average 4- to 5-fold increase in the palifermin AUC and an 80% decrease in palifermin clearance compared to palifermin alone.<sup>1,2</sup> Assessment of palifermin effects using a surrogate measure for cell proliferation indicated no significant impact on palifermin effects. There was no significant effect of palifermin on heparin activity as measured by aPTT. A slightly, but not clinically relevant, lower effect of palifermin was observed when palifermin 40 mcg/kg/day IV bolus was coadministered with unfractionated heparin for three consecutive days compared to palifermin alone.<br><br>The mechanism of this interaction is unknown, but the authors propose the observed interaction may be a result of heparin binding to low-affinity keratinocyte growth factor binding sites.<sup>1</sup> In vitro and in vivo data showed that palifermin interacts with low molecular weight heparins as well.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yang BB, Gillespie B, Smith B, et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. <i>J Clin Pharmacol</i>. 2015; Apr 15. doi: 10.1002/jcph.516 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25880826\">[PubMed 25880826]</a></p>\n<p>2. Kepivance (palifermin) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9306":"<p><b>Title</b> Palifermin / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of palifermin-related toxicities.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> According to the palifermin prescribing information, in vitro and in vivo data showed that palifermin interacts with both unfractionated heparin (UFH) and low molecular weight heparins,<sup>1</sup> although published data are only available for UFH.<br><br>One study of healthy subjects found that coadministration with a single IV bolus dose of palifermin 60 mcg/kg and therapeutic levels of unfractionated heparin resulted in an average 4- to 5-fold increase in the palifermin AUC and an 80% decrease in palifermin clearance compared to palifermin alone.<sup>1,2</sup> Assessment of palifermin effects using a surrogate measure for cell proliferation indicated no significant impact on palifermin effects. There was no significant effect of palifermin on heparin activity as measured by aPTT. A slightly, but not clinically relevant, lower effect of palifermin was observed when palifermin 40 mcg/kg/day IV bolus was coadministered with unfractionated heparin for three consecutive days compared to palifermin alone.<br><br>The mechanism of this interaction is unknown, but the authors propose the observed interaction may be a result of heparin binding to low-affinity keratinocyte growth factor binding sites.<sup>2</sup> In vitro and in vivo data showed that palifermin interacts with low molecular weight heparins as well.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kepivance (palifermin) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); May 2013.</p>\n<p>2. Yang BB, Gillespie B, Smith B, et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. <i>J Clin Pharmacol</i>. 2015; Apr 15. doi: 10.1002/jcph.516 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25880826\">[PubMed 25880826]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9307":"<p><b>Title</b> Sotalol / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Sotalol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid simultaneous administration of sotalol and antacids. If concomitant therapy is necessary, administer antacids 2 hours after sotalol.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, the simultaneous administration of a single dose of an aluminum oxide/magnesium hydroxide (1,800 mg/1,200 mg) antacid with sotalol (160 mg single oral dose) reduced the sotalol AUC and maximum serum concentration (Cmax) 21% and 27%, respectively.<sup>1,2</sup> The effect of sotalol on heart rate reduction was diminished in the presence of the antacid. The antacid had no effect on sotalol pharmacokinetics or pharmacodynamics when administered 2 hours after sotalol.<sup>1,2</sup> In another pharmacokinetic study of 5 healthy volunteers, the concomitant administration of sotalol (160 mg single oral dose) and magnesium hydroxide reduced the sotalol AUC and Cmax 16%, but concomitant administration of sotalol and aluminum hydroxide or calcium carbonate had no effect on sotalol pharmacokinetics.<sup>3</sup><br><br>Sotalol prescribing information states that the administration of sotalol within 2 hours of antacids containing magnesium hydroxide or aluminum oxide should be avoided.<sup>2</sup> Administration of antacids 2 hours after sotalol is recommended.<sup>2</sup><br><br>The mechanism of this potential interaction is likely adsorption of sotalol onto the antacid, forming a poorly absorbable complex leading to decreased sotalol exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. <i>Br J Clin Pharmacol</i>. 1997;43(3):269-272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9088581\">[PubMed 9088581]</a></p>\n<p>2. Betapace (sotalol) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2011.</p>\n<p>3. Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. <i>Acta Pharmacol Toxicol (Copenh)</i>. 1981;49(3):181-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7336975\">[PubMed 7336975]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9308":"<p><b>Title</b> Atenolol / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Atenolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, an aluminum hydroxide/magnesium hydroxide antacid reduced the atenolol (100 mg single oral dose) AUC and maximum serum concentration (Cmax) 33% and 37%, respectively.<sup>1</sup> In another study of 6 healthy volunteers, calcium 500 mg (as the lactate, gluconate, or carbonate salt) decreased the atenolol (100 mg single oral dose) AUC and Cmax 32% and 51%, respectively, and inhibition of exercise-induced tachycardia was reduced.<sup>2</sup> When calcium was given after 6 days of atenolol therapy, the atenolol AUC and Cmax only decreased 13% and 21%, respectively, and no change in blood pressure was seen. When atenolol (single dose or 6-day treatment course) was given with aluminum hydroxide (5.6 g), no significant change in atenolol pharmacokinetics was obseved.<sup>2</sup><br><br>The mechanism of this potential interaction is unknown, but may be related to the formation of an antacid/atenolol complex in the GI tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. <i>Biopharm Drug Dispos</i>. 1981;2(1):79-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7236872\">[PubMed 7236872]</a></p>\n<p>2. Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. <i>Clin Pharmacol Ther</i>. 1981;30(4):429-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7285476\">[PubMed 7285476]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9309":"<p><b>Title</b> Tasimelteon / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tasimelteon effects/toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 4 days) increased the tasimelteon (20 mg single oral dose) AUC and maximum serum concentration 55% and 33%, respectively.<sup>1,2</sup><br><br>The mechanism of this interaction is likely CYP3A4 inhibition by ketoconazole, an enzyme partially responsible for tasimelteon metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hetlioz (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; December 2014.</p>\n<p>2. Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. [published online April 6, 2015]. <i>J Clin Pharmacol</i>. Doi: 10.1002/jcph.507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25851638\">[PubMed 25851638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9310":"<p><b>Title</b> Choline C 11 / Colchicine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Colchicine may diminish the therapeutic effect of Choline C 11. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for imaging errors with choline C 11 if used in patients taking colchicine. Consider stopping colchicine for at least 5 days (approximately 5 half-lives) prior to choline C 11 imaging.</p> \n<p><b>Discussion</b> One case report describes a 73-year-old man with prostate cancer who received a PET/CT scan with methylcholine F18 while taking colchicine 0.5 mg once daily.<sup>1</sup> The image revealed an abnormal distribution of methylcholine F18 with no active uptake in any relevant organ and the images were determined to be uninterpretable and nondiagnostic for restaging of prostate cancer. It was suspected that colchicine was responsible for impaired choline metabolism. The patient discontinued colchicine therapy for 2 weeks and a repeat scan revealed a normal distribution of methylcholine F18.<sup>1</sup><br><br>Prescribing information for choline C 11 states that colchicine may interfere with choline C 11 imaging and that a negative image does not rule out the presence of prostate cancer.<sup>2</sup><br><br>The mechanism of this suspected interaction is that colchicine may increase one pathway of choline metabolism altering its uptake into rapidly dividing cells (eg, prostate tumors) leading to uniterpretable images.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Roef MJ, van der Poel H, van der Laken CJ, Vogel WV. Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT. <i>Nucl Med Commun</i>. 2010;31(12):1075-1077. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21089227\">[PubMed 21089227]</a></p>\n<p>2. Choline C 11 injection [prescribing information]. Rochester, MN: Mayo Clinic PET Radiochemistry Facility; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9311":"<p><b>Title</b> Choline C 11 / Antiandrogens</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antiandrogens may diminish the therapeutic effect of Choline C 11. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for imaging errors with choline C 11 if used in patients taking antiandrogens. The impact of antiandrogens on choline C 11 images may be most concerning in patients with hormone responsive prostate cancer.</p>\n<div>\n <p><b>Antiandrogens Interacting Members</b> Abiraterone Acetate, Apalutamide, Bicalutamide, Cyproterone, Enzalutamide, Flutamide, Ketoconazole (Systemic), MedroxyPROGESTERone, Megestrol, Nilutamide</p>\n</div> \n<p><b>Discussion</b> In one analysis of 14 patients with prostate cancer, choline C 11 PET/CT scans were administered before, and 6 months after, hormone-deprivation therapy.<sup>1</sup> Before hormone-deprivation therapy, 13 patients had positive scans for metastatic spread, but after therapy, only 4 scans remained positive. Reduced choline C 11 uptake and negative scans were seen in patients who responded to hormone-deprivation therapy. Patients who still had elevated prostate specific antigen levels despite hormone-deprivation therapy continued to have positive scans.<sup>1</sup> In another analysis of 6 patients, a significant reduction in choline C 11 update was observed after 4 months of bicalutamide therapy compared with choline C 11 uptake prior to starting bicalutamide.<sup>2</sup> In vitro studies of prostate cancer cell lines have also shown choline uptake inhibition by bicalutamide and flutamide.<sup>3,4</sup><br><br>Prescribing information for choline C 11 states that antiandrogens may interfere with choline C 11 imaging and that a negative image does not rule out the presence of prostate cancer.<sup>5</sup> The impact of antiandrogens on choline C 11 imaging may depend on the hormonal responsiveness of a patient’s recurrent prostate cancer, as some reports suggest choline C 11 imaging may still be productive in patients with “hormone-resistant” recurrent prostate cancer even if they are receiving antiandrogens.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fuccio C, Schiavina R, Castellucci P, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. <i>Eur J Nucl Med Mol Imaging</i>. 2011;38(11):1985-1989. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21732105\">[PubMed 21732105]</a></p>\n<p>2. Giovacchini G, Picchio M, Coradeschi E, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. <i>Eur J Nucl Med Mol Imaging</i>. 2008;35(6):1065-1073. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18200444\">[PubMed 18200444]</a></p>\n<p>3. Muller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. <i>Eur J Nucl Med Mol Imaging</i>. 2009;36(9):1434-1442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19352653\">[PubMed 19352653]</a></p>\n<p>4. Al-Saeedi F. Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. <i>Curr Ther Res Clin Exp</i>. 2007;68(4):226-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24683213\">[PubMed 24683213]</a></p>\n<p>5. Choline C 11 injection [prescribing information]. Rochester, MN: Mayo Clinic PET Radiochemistry Facility; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9312":"<p><b>Title</b> Choline C 11 / Luteinizing Hormone-Releasing Hormone Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for imaging errors with choline C 11 if used in patients taking luteinizing hormone-releasing hormone (LHRH) analogs. The impact of LHRH analogs on choline C11 images may be of most concern in patients with hormone-responsive prostate cancer.</p>\n<div>\n <p><b>Luteinizing Hormone-Releasing Hormone Analogs Interacting Members</b> Buserelin, Goserelin, Histrelin, Leuprolide, Nafarelin, Triptorelin</p>\n</div> \n<p><b>Discussion</b> In one analysis of 14 patients with prostate cancer, choline C 11 PET/CT scans were administered before, and 6 months after, hormone-deprivation therapy.<sup>1</sup> Before hormone-deprivation therapy, 13 patients had positive scans for metastatic spread, but after therapy, only 4 scans remained positive. Reduced choline C 11 uptake and negative scans were seen in patients who responded to hormone-deprivation therapy. Patients who still had elevated prostate specific antigen levels despite hormone-deprivation therapy continued to have positive scans.<sup>1</sup> In another analysis of 6 patients, a significant reduction in choline C 11 update was observed after 4 months of bicalutamide therapy compared with choline C 11 uptake prior to starting bicalutamide.<sup>2</sup> In vitro studies of prostate cancer cell lines have also shown choline uptake inhibition by bicalutamide and flutamide.<sup>3,4</sup><br><br>Prescribing information for choline C 11 states that LHRH analogs may interfere with choline C 11 imaging and that a negative image does not rule out the presence of prostate cancer.<sup>5</sup> The impact of LHRH analogs on choline C 11 imaging may depend on the hormonal responsiveness of a patient’s recurrent prostate cancer, as some reports suggest choline C 11 imaging may still be productive in patients with “hormone-resistant” recurrent prostate cancer even if they are receiving LHRH analog therapy.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fuccio C, Schiavina R, Castellucci P, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. <i>Eur J Nucl Med Mol Imaging</i>. 2011;38(11):1985-1989. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21732105\">[PubMed 21732105]</a></p>\n<p>2. Giovacchini G, Picchio M, Coradeschi E, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. <i>Eur J Nucl Med Mol Imaging</i>. 2008;35(6):1065-1073. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18200444\">[PubMed 18200444]</a></p>\n<p>3. Muller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. <i>Eur J Nucl Med Mol Imaging</i>. 2009;36(9):1434-1442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19352653\">[PubMed 19352653]</a></p>\n<p>4. Al-Saeedi F. Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. <i>Curr Ther Res Clin Exp</i>. 2007;68(4):226-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24683213\">[PubMed 24683213]</a></p>\n<p>5. Choline C 11 injection [prescribing information]. Rochester, MN: Mayo Clinic PET Radiochemistry Facility; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9313":"<p><b>Title</b> Propranolol / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction does not apply to the intravenous administration of propranolol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aluminum Hydroxide may decrease the serum concentration of Propranolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, when aluminum hydroxide gel (30 mL single oral dose) was given with propranolol (40 mg single oral dose) the pharmacokinetics of propranolol were essentially unchanged.<sup>1</sup> Small numeric changes in the maximum serum concentration and AUC were reported, but no changes reached statistical significance. The pharmacodynamic response to propranolol during exercise was also unchanged.<sup>1</sup><br><br>Prescribing information for propranolol states that coadministration with aluminum hydroxide gel may result in a decrease in propranolol concentrations, but provides no data to support this claim.<sup>2</sup><br><br>The mechanism of this proposed interaction may relate to prolongation of gastric emptying time or adsorption of propranolol by aluminum hydroxide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1985;23(5):244-246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4008113\">[PubMed 4008113]</a></p>\n<p>2. Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9314":"<p><b>Title</b> Bedaquiline / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of bedaquiline with moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 33 healthy volunteers, the bedaquiline (400 mg single oral dose) AUC was reduced 18% when coadministered on day 29 of a 43-day treatment regimen of the moderate CYP3A4 inducer efavirenz (600 mg once daily).<sup>1</sup> The M2-metabolite AUC was not significantly changed, but the M2-metabolite maximum serum concentration (Cmax) increased by an average of 89%.<sup>1</sup> Due to the long half-life of bedaquiline, the reduction in exposure seen when coadministered with efavirenz may be greater with steady-state bedaquiline. Although the effect of efavirenz on bedaquiline at steady-state has not been directly evaluated, a population pharmacokinetic modeling study predicted that exposure to bedaquiline would be reduced by 50% when both drugs were at steady-state.<sup>2</sup><br><br>Due to the potential for moderate CYP3A4 inducers to significantly lower exposure to bedaquiline, prescribing information for bedaquiline recommends avoidance of moderate CYP3A4 inducers during bedaquiline treatment.<sup>3</sup> <br><br>The suspected primary mechanism of this interaction is increased CYP3A4-mediated bedaquiline metabolism by moderate CYP3A4 inducers such as efavirenz.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dooley KE, Park JG, Swindells S, et al; ACTG 5267 Study Team. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. <i>J Acquir Immune Defic Syndr</i>. 2012;59(5):455-462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22126739\">[PubMed 22126739]</a></p>\n<p>2. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. <i>Antimicrob Agents Chemother</i>. 2013;57(6):2780-2787. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23571542\">[PubMed 23571542]</a></p>\n<p>3. Sirturo (bedaquiline) [prescribing information]. Titusville, NJ: Janssen Products LP; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9315":"<p><b>Title</b> BCG Vaccine (Immunization) / Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer BCG vaccine and antibiotics cautiously in combination due to the potential for diminished immune response to the vaccination.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Systemic), Bacampicillin, Bacitracin (Systemic), Bedaquiline, Benzoin, Capreomycin, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Flomoxef, Flucloxacillin, Fosfomycin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Gentian Violet, Hexachlorophene, Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Mafenide, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Neomycin, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxychlorosene, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Oral Inhalation), Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Polymyxin B, Povidone-Iodine (Topical), Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, RifAXIMin, Roxithromycin, Secnidazole, Silver Nitrate, Silver Sulfadiazine, Sparfloxacin, Spiramycin, Streptomycin, Sulfacetamide (Topical), SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Taurolidine, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Aztreonam (Oral Inhalation), Bacitracin (Ophthalmic), Bacitracin (Topical), Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Fidaxomicin, Framycetin, Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), MetroNIDAZOLE (Topical), Mupirocin, Nitrofurazone, Ozenoxacin, Sulfacetamide (Ophthalmic), Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> Product labeling for the BCG vaccine warns of potential diminished efficacy if combined with antibiotics.<sup>1</sup> Antibiotics with activity against mycobacteria are likely of greatest concern, although product labeling makes no distinction among available agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. BCG Vaccine [prescribing information]. Roseland, NJ: Organon USA Inc; January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9316":"<p><b>Title</b> BCG (Intravesical) / Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of intravesical BCG and antibiotics, particularly those given via intravenous or oral routes and those with activity against mycobacteria.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Systemic), Bacampicillin, Bacitracin (Systemic), Bedaquiline, Benzoin, Capreomycin, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Flomoxef, Flucloxacillin, Fosfomycin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Gentian Violet, Hexachlorophene, Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Mafenide, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Neomycin, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxychlorosene, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Oral Inhalation), Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Polymyxin B, Povidone-Iodine (Topical), Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, RifAXIMin, Roxithromycin, Secnidazole, Silver Nitrate, Silver Sulfadiazine, Sparfloxacin, Spiramycin, Streptomycin, Sulfacetamide (Topical), SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Taurolidine, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Aztreonam (Oral Inhalation), Bacitracin (Ophthalmic), Bacitracin (Topical), Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Fidaxomicin, Framycetin, Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), MetroNIDAZOLE (Topical), Mupirocin, Nitrofurazone, Ozenoxacin, Sulfacetamide (Ophthalmic), Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> US prescribing information for intravesical BCG states that therapy should be suspended during treatment with antibiotics because antibiotics may interfere with the clinical response to therapy.<sup>1,2</sup> Although in vitro testing suggests that BCG may be resistant to several antibiotics,<sup>3,4,5</sup> and antibiotics with activity against mycobacteria are likely of greatest concern, avoidance of all antimicrobial therapy during treatment is currently recommended.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. TICE BCG (BCG live) [prescribing information]. Roseland, NJ: Organon USA Inc; February 2009.</p>\n<p>2. TheraCys (BCG live) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; November 2012.</p>\n<p>3. Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Interference of modern antibacterials with bacillus Calmette-Guerin viability. <i>J Urol</i>. 1999;162(6):1959-1962. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10569547\">[PubMed 10569547]</a></p>\n<p>4. Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Sensitivity of BCG to modern antibiotics. <i>Eur Urol</i>. 2000;37(suppl 1):21-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10575268\">[PubMed 10575268]</a></p>\n<p>5. van der Meijden PM, van Klingeren B, Steerenberg PA, de Boer LC, de Jong WH, Debruyne FM. The possible influence of antibiotics on results of bacillus Calmette-Guerin intravesical therapy for superficial bladder cancer. <i>J Urol</i>. 1991;146(2):444-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1856950\">[PubMed 1856950]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9317":"<p><b>Title</b> Norgestimate / RifAXIMin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAXIMin may decrease the serum concentration of Norgestimate. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 26 healthy female volunteers, rifaximin (200 mg every 8 hours for 4 days) had no effect on the pharmacokinetics of the active metabolites of norgestimate (norgestrel or 17-deacetyl norgestimate) when given as a single oral dose of norgestimate 0.5 mg and ethinyl estradiol 0.07 mg. <sup>1</sup> In a study of 39 healthy volunteers described in the rifaximin prescribing information, rifaximin (550 mg every 8 hours for 7 days) decreased the norgestimate (given as a single oral dose of norgestimate 0.25 mg and ethinyl estradiol 0.025 mg) maximum serum concentration 25% and decreased the AUC of the active metabolites 7% to 11%.<sup>2</sup> The clinical relevance of these changes is unknown.<br><br>The primary mechanism of this potential interaction is unknown, but rifaximin induction of CYP3A4 or inhibition of enterohepatic recycling by SLCO/OATP transporters may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. <i>Ann Pharmacother</i>. 2007;41(2):222-228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17284510\">[PubMed 17284510]</a></p>\n<p>2. Xifaxan (rifaximin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9318":"<p><b>Title</b> Ethinyl Estradiol / RifAXIMin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAXIMin may decrease the serum concentration of Ethinyl Estradiol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 26 healthy female volunteers, rifaximin (200 mg every 8 hours for 4 days) had no effect on the pharmacokinetics of ethinyl estradiol (given as a single oral dose of norgestimate 0.5 mg and ethinyl estradiol 0.07 mg). <sup>1</sup> In a study of 39 healthy volunteers described in the rifaximin prescribing information, rifaximin (550 mg every 8 hours for 7 days) decreased the ethinyl estradiol (given as a single oral dose of norgestimate 0.25 mg and ethinyl estradiol 0.025 mg) maximum serum concentration 13% but had no effect on the ethinyl estradiol AUC.<sup>2</sup> The clinical relevance of these changes is unknown.<br><br>The primary mechanism of this potential interaction is unknown, but rifaximin induction of CYP3A4 or inhibition of enterohepatic recycling by SLCO/OATP transporters may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. <i>Ann Pharmacother</i>. 2007;41(2):222-228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17284510\">[PubMed 17284510]</a></p>\n<p>2. Xifaxan (rifaximin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9319":"<p><b>Title</b> Propafenone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased propafenone effects/therapeutic failure in patients receiving strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers who were CYP2D6 extensive metabolizers (EMs), the strong CYP3A4 inducer, rifampin (600 mg once daily for 9 days) had no effect on the pharmacokinetics of intravenous (IV) propafenone (70 mg single dose), but decreased the AUC and maximum serum concentration (Cmax) of oral propafenone (300 mg single dose) 83% and 85%, respectively.<sup>1</sup> The bioavailability of oral propafenone was reduced from 30% to 4% with rifampin.<sup>1</sup> In another pharmacokinetic study, rifampin (600 mg once daily for 9 days) decreased the propafenone (300 mg single oral dose) AUC and Cmax 73% and 63%, respectively, in 6 healthy volunteers who were CYP2D6 EM.<sup>2</sup> The pharmacokinetics of IV propafenone were unaffected by rifampin.<sup>2</sup> In 6 CYP2D6 poor metabolizers, rifampin decreased the AUC of IV propafenone (140 mg single dose) 51%, but had no effect on the Cmax, and rifampin decreased the oral propafenone AUC and Cmax 71% and 53%, respectively.<sup>2</sup> Lastly, one case report describes a 42-year-old man on long-term propafenone who experienced breakthrough arrhythmias and reduced serum propafenone levels after initiation of rifampin. His serum levels returned to therapeutic concentrations and his arrhythmias ceased after rifampin was discontinued.<sup>3</sup><br><br>The mechanism of this interaction has not been fully investigated, but induction of CYP3A4 mediated metabolism of propafenone by rifampin is likely. Other strong CYP3A4 inducers may pose a similar risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. <i>Clin Pharmacol Ther</i>. 2000;67(5):512-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10824630\">[PubMed 10824630]</a></p>\n<p>2. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. <i>Pharmacogenetics</i>. 1999;9(5):551-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10591535\">[PubMed 10591535]</a></p>\n<p>3. Castel JM, Cappiello E, Leopaldi D, Latini R. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect. <i>Br J Clin Pharmacol</i>. 1990;30(1):155-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2390428\">[PubMed 2390428]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9320":"<p><b>Title</b> BCG (Intravesical) / Immunosuppressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of intravesical BCG with immunosuppressants. US prescribing information specifically lists this as a contraindication.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Cytarabine (Liposomal), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> US prescribing information for intravesical BCG states that its use should be avoided with immunosuppressant agents because immunosuppression may interfere with the clinical response to therapy.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. TICE BCG (BCG live) [prescribing information]. Roseland, NJ: Organon USA Inc; February 2009.</p>\n<p>2. TheraCys (BCG live) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9321":"<p><b>Title</b> BCG (Intravesical) / Myelosuppressive Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of intravesical BCG with myelosuppressive agents. US prescribing information specifically lists this as a contraindication.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> US prescribing information for intravesical BCG states that its use should be avoided with myelosuppressive agents because myelosuppression may interfere with the clinical response to therapy.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. TICE BCG (BCG live) [prescribing information]. Roseland, NJ: Organon USA Inc; February 2009.</p>\n<p>2. TheraCys (BCG live) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9322":"<p><b>Title</b> Artesunate / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nevirapine may decrease serum concentrations of the active metabolite(s) of Artesunate. Nevirapine may increase the serum concentration of Artesunate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of diminished response to artesunate if used with nevirapine.</p> \n<p><b>Discussion</b> The artesunate AUC was was increased by an average of 45% in HIV-positive patients receiving nevirapine (n=11) compared to control patients who were not receiving antiretroviral therapy (n=10).<sup>1</sup> Patients in both groups received artesunate-amodiaquine (200 mg/600 mg daily) for three days. Exposure to dihydroartemisinin (the active metabolite that accounts for most or all of clinical antimalarial activity) was an average of 32% lower in the nevirapine group; however, this difference was not statistically significant. The specific mechanism for and clinical significance of this reported interaction are both uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fehintola FA, Scarsi KK, Ma Q, et al. Nevirapine-based antiretroviral therapy impacts artesunate and dihydroartemisinin disposition in HIV-infected nigerian adults. <i>AIDS Res Treat</i>. 2012;2012:703604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22500218\">[PubMed 22500218]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9323":"<p><b>Title</b> Barnidipine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of barnidipine and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Barnidipine Korean prescribing information states that use with strong CYP3A4 inhibitors should be avoided due to the potential for increased barnidipine exposure and effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oldeca (barnidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199300656. Accessed December 15, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9324":"<p><b>Title</b> Barnidipine / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Barnidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of barnidipine and erythromycin.</p> \n<p><b>Discussion</b> Barnidipine Korean prescribing information states that use with strong CYP3A4 inhibitors should be avoided due to the potential for increased barnidipine exposure and effects.<sup>1</sup> Erythromycin is specifically listed as a CYP3A4 inhibitor to avoid, although most clinical data characterize it as a moderate rather than strong inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Oldeca (barnidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199300656. Accessed December 15, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9325":"<p><b>Title</b> Digoxin / Barnidipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barnidipine may enhance the adverse/toxic effect of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination for increased effects of digoxin, particularly signs and symptoms of toxicity such as nausea, vomiting, dizziness, bradycardia, and arrhythmia.</p> \n<p><b>Discussion</b> Barnidipine Korean prescribing information states that it may enhance digoxin effects, which may increase the risk of signs and symptoms of toxicity (eg, nausea, vomiting, dizziness, bradycardia, arrhythmia) and necessitate digoxin dose reduction. The mechanism of this possible interaction is unclear. Barnidipine could theoretically increase digoxin exposure via inhibition of its P-glycoprotein-mediated efflux.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oldeca (barnidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199300656. Accessed December 15, 2014.</p>\n<p>2. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. <i>Pharm Res</i>. 2000;17(10):1189-1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11145223\">[PubMed 11145223]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9326":"<p><b>Title</b> Dextromethorphan / Parecoxib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Parecoxib may increase the serum concentration of Dextromethorphan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased dextromethorphan effects/toxicities if combined with parecoxib.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the parecoxib product label, administration of valdecoxib (the active moiety of the prodrug parecoxib) at a dose of 40 mg twice daily for 7 days increased the plasma concentrations of dextromethorphan 3-fold.<sup>1</sup><br><br>Product labeling for parecoxib states that CYP2D6 inhibition by parecoxib is the likely mechanism for this interaction.<sup>1</sup> However, in a pharmacokinetic study of 15 healthy volunteers, valdecoxib (20 mg daily for 7 days) had no effect on the pharmacokinetics of the CYP2D6 probe drug, metoprolol.<sup>2</sup> As such, the mechanism behind the interaction between parecoxib and dextromethorphan is still largely unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dynastat (parecoxib) [summary of product characteristics]. Sandwich, Kent, UK: Pfizer Limited; December 2014.</p>\n<p>2. Werner U, Lamprecht C, Werner D, et al. Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. <i>Int J Clin Pharmacol Ther</i>. 2006;44(9):397-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16995327\">[PubMed 16995327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9327":"<p><b>Title</b> Parecoxib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased parecoxib effects/toxicities if combined with a strong CYP3A4 inhibitor. Drugs that inhibit both CYP3A4 and CYP2C9 may have a greater effect.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the parecoxib product label, ketoconazole increased the valdecoxib (the active moiety of the prodrug parecoxib) AUC and maximum serum concentration 38% and 24%, respectively.<sup>1</sup> Product labeling states that a parecoxib dose reduction is generally not necessary with this combination.<sup>1</sup><br><br>The proposed mechanism of this interaction is CYP3A4 inhibition by ketoconazole, an enzyme partially responsible for valdecoxib metabolism.<sup>1</sup> Ketoconazole inhibition of CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dynastat (parecoxib) [summary of product characteristics]. Sandwich, Kent, UK: Pfizer Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9329":"<p><b>Title</b> Parecoxib / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Parecoxib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use the lowest effective dose of parecoxib in patients taking fluconazole.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the parecoxib product label, administration of fluconazole increased the AUC and maximum serum concentration of valdecoxib (the active moiety of the prodrug parecoxib) 62% and 19%, respectively.<sup>1</sup><br><br>Product labeling for parecoxib recommends a dose reduction or use of the lowest effective dose of parecoxib in patients taking fluconazole.<sup>1</sup><br><br>The suspected mechanism of this interaction is fluconazole inhibition of CYP2C9 and CYP3A4, enzymes responsible for the metabolism of valdecoxib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dynastat (parecoxib) [summary of product characteristics]. Sandwich, Kent, UK: Pfizer Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9330":"<p><b>Title</b> Eluxadoline / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with cyclosporine and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, such as cyclosporine, and patients should be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9331":"<p><b>Title</b> Rosuvastatin / Eluxadoline</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Eluxadoline may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use the lowest effective dose of rosuvastatin if combined with eluxadoline.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the eluxadoline prescribing information, administration of eluxadoline (100 mg twice daily for multiple doses) increased the rosuvastatin (20 mg single dose) AUC and maximum serum concentration 40% and 18%, respectively.<sup>1</sup> Similar results were observed with the active, major metabolite, n-desmethyl rosuvastatin.<sup>1</sup><br><br>Eluxadoline prescribing information states that the combination of eluxadoline and rosuvastatin may increase the risk of muscle toxicity/rhabdomyolysis and recommends using the lowest effective dose of rosuvastatin.<br><br>The likely mechanism of this potential interaction is OATP1B1/SLCO1B1 inhibition by eluxadoline, a transporter responsible for rosuvastatin hepatic uptake. Eluxadoline inhibition of BCRP may also play a role, however it has been reported that eluxadoline did not inhibit BCRP in vitro.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>2. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9332":"<p><b>Title</b> Eluxadoline / Alosetron</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alosetron may enhance the constipating effect of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of eluxadoline and alosetron.</p> \n<p><b>Discussion</b> Prescribing information for eluxadoline recommends avoiding the use of eluxadoline with other medications that cause constipation, specifically listing alosetron, due to the risk for constipation related adverse events.<sup>1</sup> <br><br>The suspected mechanism of this interaction is an additive constipating effect, as both eluxadoline and alosetron independently increase the risk of constipation and related adverse events.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>2. Lotronex (alosetron) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9333":"<p><b>Title</b> Eluxadoline / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Opioid Analgesics may enhance the constipating effect of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of eluxadoline and opioid analgesics.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> Prescribing information for eluxadoline recommends avoiding the use of eluxadoline with other medications that cause constipation, specifically listing opioid analgesics, due to the risk for constipation related adverse events.<sup>1</sup> <br><br>The suspected mechanism of this interaction is an additive constipating effect, as both eluxadoline and opioids independently increase the risk of constipation and related adverse events.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9334":"<p><b>Title</b> Eluxadoline / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of eluxadoline and anticholinergic agents.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Prescribing information for eluxadoline recommends avoiding the use of eluxadoline with other medications that cause constipation, specifically listing anticholinergic agents, due to the risk for constipation related adverse events.<sup>1</sup> <br><br>The suspected mechanism of this interaction is an additive constipating effect, as both eluxadoline and anticholinergic agents independently increase the risk of constipation and related adverse events.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9335":"<p><b>Title</b> Eluxadoline / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Eluxadoline. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, probenecid (500 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 1.4- and 1.3-fold, respectively.<sup>1,2</sup> Renal clearance of eluxadoline decreased 47%.<sup>1</sup><br><br>Prescribing information for eluxadoline states that the increase in eluxadoline exposure seen with probenecid is unlikely to be clinically significant and no dose adjustment is required if these agents are combined.<br><br>The proposed mechanism of this interaction is probenecid inhibition of OAT3 in the kidney, a transporter thought to be responsible for eluxadoline renal elimination.<sup>1,2</sup> Probenecid inhibition of MRP2 may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9336":"<p><b>Title</b> Eluxadoline / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Gemfibrozil may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with gemfibrozil and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing gemfibrozil as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. In vitro and clinical evidence suggests that gemfibrozil also inhibits OATP1B1/SLCO1B1.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. <i>Xenobiotica</i>. 2007;37(5):474-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17523051\">[PubMed 17523051]</a></p>\n<p>4. Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. <i>Xenobiotica</i>. 2005;35(7):737-753. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16316932\">[PubMed 16316932]</a></p>\n<p>5. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. <i>J Pharmacol Exp Ther</i>. 2004;311(1):228-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15194707\">[PubMed 15194707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9337":"<p><b>Title</b> Eluxadoline / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with atazanavir and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing atazanavir as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. In vitro evidence suggests that atazanavir may also inhibit OATP1B1/SLCO1B1.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. <i>Pharm Res</i>. 2012;29(2):411-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21861202\">[PubMed 21861202]</a></p>\n<p>4. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p>5. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, Bow DA. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. <i>Xenobiotica</i>. 2014;44(3):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23886114\">[PubMed 23886114]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9338":"<p><b>Title</b> Eluxadoline / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with lopinavir and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing lopinavir as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. In vitro evidence suggests that lopinavir may inhibit OATP1B1/SLCO1B1.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. <i>Pharm Res</i>. 2012;29(2):411-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21861202\">[PubMed 21861202]</a></p>\n<p>4. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9339":"<p><b>Title</b> Eluxadoline / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with ritonavir and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing ritonavir as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. Some in vitro suggests that ritonavir may inhibit OATP1B1/SLCO1B1,<sup>3,4,5</sup> while one clinical study suggests little to no inhibition by ritonavir.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p>4. Izumi S, Nozaki Y, Komori T, et al. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein. <i>Drug Metab Dispos</i>. 2013;41(10):1859-1866. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23920221\">[PubMed 23920221]</a></p>\n<p>5. Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. <i>J Pharm Sci</i>. 2013;102(9):3427-3435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23440887\">[PubMed 23440887]</a></p>\n<p>6. Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. <i>J Clin Pharmacol</i>. 2012;52(11):1725-1738. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22174437\">[PubMed 22174437]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9340":"<p><b>Title</b> Eluxadoline / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with saquinavir and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing saquinavir as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. In vitro evidence suggests that saquinavir may also inhibit OATP1B1/SLCO1B1.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p>4. Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. <i>J Pharm Sci</i>. 2013;102(9):3427-3435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23440887\">[PubMed 23440887]</a></p>\n<p>5. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, Bow DA. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. <i>Xenobiotica</i>. 2014;44(3):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23886114\">[PubMed 23886114]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9341":"<p><b>Title</b> Eluxadoline / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with tipranavir and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing tipranavir as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. Although in vitro evidence suggests that several protease inhibitors may inhibit OATP1B1/SLCO1B1,<sup>3,4,5,6</sup> specific evidence for tipranavir inhibition of OATP1B1/SLCO1B1 is more limited.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. <i>Pharm Res</i>. 2012;29(2):411-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21861202\">[PubMed 21861202]</a></p>\n<p>4. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p>5. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, Bow DA. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. <i>Xenobiotica</i>. 2014;44(3):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23886114\">[PubMed 23886114]</a></p>\n<p>6. Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. <i>J Pharm Sci</i>. 2013;102(9):3427-3435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23440887\">[PubMed 23440887]</a></p>\n<p>7. Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9342":"<p><b>Title</b> Eluxadoline / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with rifampin and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing rifampin as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. Evidence from in vitro and clinical studies suggests that rifampin may also inhibit OATP1B1/SLCO1B1.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Prueksaritanont T, Chu X, Evers R, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. <i>Br J Clin Pharmacol</i>. 2014;78(3):587-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24617605\">[PubMed 24617605]</a></p>\n<p>4. Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. <i>Clin Ther</i>. 2014;36(2):280-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24491572\">[PubMed 24491572]</a></p>\n<p>5. Chen Y, Zhang W, Huang WH, et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 2013;69(11):1933-1938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23831870\">[PubMed 23831870]</a></p>\n<p>6. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, Bow DA. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. <i>Xenobiotica</i>. 2014;44(3):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23886114\">[PubMed 23886114]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9343":"<p><b>Title</b> Eluxadoline / Eltrombopag</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Eltrombopag may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined with eltrombopag and monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities<br>needed to drive a car or operate machinery, constipation, abdominal pain).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing eltrombopag as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. Evidence from in vitro and clinical studies suggests that eltrombopag inhibits OATP1B1/SLCO1B1.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9344":"<p><b>Title</b> Ezogabine / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Ezogabine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider increasing the ezogabine dose when adding phenytoin. Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy. Conversely, patients stable on this combination may need to have their ezogabine dose reduced if phenytoin is discontinued.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> The ezogabine AUC was decreased by an average of 34% when administered with phenytoin (120-600 mg/d) in a study described in the ezogabine prescribing information.<sup>1</sup> As a result of this decrease in ezogabine exposure, the prescribing information recommends consideration of using increased ezogabine doses when used with phenytoin.<br><br>The specific mechanism for this apparent interaction is unknown, but enhanced glucuronidation and/or acetylation of ezogabine is possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Potiga (ezogabine). Research Triangle Park, NC: GlaxoSmithKline, 06/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9345":"<p><b>Title</b> Tacrolimus (Systemic) / Efonidipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efonidipine may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor tacrolimus therapy closely during concurrent use of efonidipine, including both tacrolimus concentrations and signs or symptoms suggestive of tacrolimus toxicity.</p> \n<p><b>Discussion</b> The labeling for efonidipine cautions that efonidipine may increase tacrolimus concentrations and/or effects.<sup>1</sup> No specific data concerning the likelihood or magnitude of the interaction are provided.<br><br>The specific mechanism for such an interaction is not clear. A study in rats suggests that efonidipine may be capable of inhibiting CYP3A4 and/or p-glycoprotein,<sup>2</sup> both of which contribute to the disposition of tacrolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Finte (efonidipine hydrochloride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200202793. Accessed December 14, 2014.</p>\n<p>2. Li C, Choi DH, Choi JS. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. <i>J Pharmacokinet Pharmacodyn</i>. 2012;39(1):99-108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22210483\">[PubMed 22210483]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9346":"<p><b>Title</b> Efonidipine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Efonidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of increased efonidipine effects such as excessive blood pressure and/or heart rate reduction.</p> \n<p><b>Discussion</b> The efonidipine AUC was an average of 67% higher with concurrent ingestion of grapefruit juice according to a study where subjects (n=19) received efonidipine 40 mg with 250 mL of grapefruit juice.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but grapefruit juice in a known inhibitor of first pass metabolism of many other dihydropyridine calcium channel blockers, suggesting that this may the mechanism for this apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Uesawa Y, Mohri K. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. <i>Yakugaku Zasshi</i>. 2008;128(1):117-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18176062\">[PubMed 18176062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9347":"<p><b>Title</b> Warfarin / Vismodegib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vismodegib may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor INR more frequently when vismodegib is initiated or discontinued in a patient on warfarin.</p> \n<p><b>Discussion</b> One case report describes a 78-year-old man stable on warfarin for 9 months (INR=2.3) who experienced an INR of 4.6 three weeks after initiation of vismodegib (150 mg daily).<sup>1</sup> Despite skipping a warfarin dose, his INR further increased to 9.5. After further warfarin dose suspension and a subsequent 36% dose reduction, his INR returned to 2.9.<sup>1</sup><br><br>The mechanism of this interaction is unknown, but vismodegib inhibition of CYP2C9-mediated warfarin metabolism has been proposed.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim S, Houranieh J, Crawford R. Elevated international normalized ratio in a patient concurrently using warfarin and vismodegib. <i>Am J Health Syst Pharm</i>. 2014;71(3):200-203. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24429012\">[PubMed 24429012]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9348":"<p><b>Title</b> AtorvaSTATin / Ticagrelor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticagrelor may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of atorvastatin toxicities when used with ticagrelor. Use particular caution in patients on higher doses of atorvastatin.</p> \n<p><b>Discussion</b> A case report describes a 62-year-old woman who experienced rhabdomyolysis two months following initiation of a regimen consisting of ticagrelor 90 mg twice daily, atorvastatin 80 mg once daily, metoprolol tartrate 25 mg twice daily, and aspirin 81 mg once daily.<sup>1</sup> The patient’s ticagrelor was subsequently switched to clopidogrel, and her atorvastatin dose was reduced. The rhabdomyolysis resolved with the patient reportedly having no further problems.<br><br>In a randomized, placebo-controlled crossover study, the maximum serum concentration and AUC of atorvastatin were 23% and 36% higher, respectively, when combined with ticagrelor, as compared to atorvastatin with placebo.<sup>2</sup> The suggested mechanism for this apparent interaction is ticagrelor inhibition of atorvastatin metabolism via CYP3A4. Atorvastatin is mostly metabolized through CYP3A4, and ticagrelor is a weak inhibitor of this enzyme, which can lead to increased plasma concentrations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kido K, Wheeler MB, Seratnahaei A, Bailey A, Bain JA. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. <i>J Am Pharm Assoc (2003)</i>. 2015;55(3):320-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26003161\">[PubMed 26003161]</a></p>\n<p>2. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 2013;69(3):477-487. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22922682\">[PubMed 22922682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9349":"<p><b>Title</b> Eluxadoline / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Eluxadoline. Specifically, alcohol use may increase the risk of pancreatitis. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Chronic or excessive short-term alcohol ingestion while taking eluxadoline should be avoided due to an increased risk of pancreatitis. Eluxadoline is contraindicated in patients with alcoholism, alcohol abuse or alcohol addiction, or in those who drink more than 3 alcoholic beverages per day.</p> \n<p><b>Discussion</b> According to the eluxadoline prescribing information, pancreatitis not associated with sphincter of Oddi spasm, was reported in 5 patients in clinical trials.<sup>1</sup> Of these 5 patients, 3 were associated with excessive alcohol intake.<sup>1</sup> All events resolved with lipase normalization upon discontinuation of eluxadoline.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9350":"<p><b>Title</b> QUEtiapine / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Methadone may enhance the QTc-prolonging effect of QUEtiapine. QUEtiapine may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of quetiapine and methadone due to the potential risks for clinically significant QT prolongation and possible pro-arrhythmic effects.</p> \n<p><b>Discussion</b> A pharmacokinetic study found a 21% increase in the (R)-methadone concentration-dose ratio but not for (S)-methadone, with concurrent quetiapine in a study of 14 patients receiving methadone maintenance treatment (MMT) with mean doses of 121 mg/day of methadone and 138 mg/day of quetiapine.<sup>1</sup> Despite the increased (R)-methadone levels, there were no instances of overmedication or intoxication. The authors conclude that this level of increase would likely not result in clinically significant effects (i.e. respiratory depression) due to the high tolerance of patients in MMT. In the same study, the lack of correlation between quetiapine plasma levels and increase of methadone concentration-dose ratios observed raises questions about whether the interaction is due to quetiapine-mediated inhibition of methadone metabolism.<br><br>A significant reduction of QTcF interval value was reported when (R,S)-methadone was replaced by a half-dose of (R)-methadone.<sup>2</sup> These findings suggest that (R)-methadone is the active enantiomer that is responsible for clinical opioid activity, and (S)-methadone is the inactive enantiomer that is responsible for QTc prolongation adverse effects.<br><br>A study of 114 schizophrenic patients randomized to receive treatment with quetiapine (400-600 mg/day) found that use of quetiapine was not associated with QTcF prolongation overall; however, 2.6% of patients experienced an increase in QTcF in excess of 30ms.<sup>3</sup> The study also considered additional surrogate markers and found that quetiapine caused no significant increase in the composite quantitative T-wave morphology combination score (MCS) score or in the analysis of Tpeak-Tend, T-wave asymmetry or flatness of the T-wave.<br><br>Product labels states the use of quetiapine should be avoided in combination with other drugs that are known to prolong QTc, including methadone.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. <i>J Clin Psychopharmacol</i>. 2007;27(3):273-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17502774\">[PubMed 17502774]</a></p>\n<p>2. Ansermot N, Albayrak O, Schlapfer J, et al. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. <i>Arch Intern Med</i>. 2010;170(6):529-536. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20308640\">[PubMed 20308640]</a></p>\n<p>3. Nielsen J, Matz J, Mittoux A, et al. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia. <i>Eur Neuropsychopharmacol</i>. 2015;25(3):303-311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25583364\">[PubMed 25583364]</a></p>\n<p>4. Seroquel XR (quetiapine fumarate) extended release tablets [prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.</p>\n<p>5. Seroquel (quetiapine fumarate) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9351":"<p><b>Title</b> Darunavir / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of rifapentine and darunavir.</p> \n<p><b>Discussion</b> US prescribing information for darunavir-containing products states that coadministration with rifapentine is not recommended due to the potential for rifapentine to decrease darunavir exposure.<sup>1,2</sup> The suspected primary mechanism of interaction between these agents is rifapentine induction of CYP3A-mediated darunavir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Products LP; May 2015.</p>\n<p>2. Prezcobix (darunavir/cobicistat) [prescribing information]. Titusville, NJ: Janssen Products LP; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9352":"<p><b>Title</b> Propafenone / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased propafenone effects/therapeutic failure in patients receiving St Johns wort.</p> \n<p><b>Discussion</b> No clinical studies have been conducted with the combination of propafenone and the moderate CYP3A4 inducer St Johns wort. However, the effect of the strong CYP3A4 inducer rifampin on the pharmacokinetics of propafenone has been evaluated.<br><br>In a pharmacokinetic study of 6 healthy volunteers who were CYP2D6 extensive metabolizers (EMs), rifampin (600 mg once daily for 9 days) had no effect on the pharmacokinetics of intravenous (IV) propafenone (70 mg single dose), but decreased the AUC and maximum serum concentration (Cmax) of oral propafenone (300 mg single dose) 83% and 85%, respectively.<sup>1</sup> The bioavailability of oral propafenone was reduced from 30% to 4% with rifampin.<sup>1</sup> In another pharmacokinetic study, rifampin (600 mg once daily for 9 days) decreased the propafenone (300 mg single oral dose) AUC and Cmax 73% and 63%, respectively, in 6 healthy volunteers who were CYP2D6 EM.<sup>2</sup> The pharmacokinetics of IV propafenone were unaffected by rifampin.<sup>2</sup> In 6 CYP2D6 poor metabolizers, rifampin decreased the AUC of IV propafenone (140 mg single dose) 51%, but had no effect on the Cmax, and rifampin decreased the oral propafenone AUC and Cmax 71% and 53%, respectively.<sup>2</sup> Lastly, one case report describes a 42-year-old man on long-term propafenone who experienced breakthrough arrhythmias and reduced serum propafenone levels after initiation of rifampin. His serum levels returned to therapeutic concentrations and his arrhythmias ceased after rifampin was discontinued.<sup>3</sup><br><br>The Canadian product monograph states that propafenone should be administered cautiously with St. John’s wort due to the potential for reduced propafenone concentrations and effects.<sup>4</sup> US prescribing information does not include this potential interaction.<sup>5</sup><br><br>The mechanism of this potential interaction is induction of CYP3A4 by St Johns wort, an enzyme that is partially responsible for propafenone metabolism.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. <i>Clin Pharmacol Ther</i>. 2000;67(5):512-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10824630\">[PubMed 10824630]</a></p>\n<p>2. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. <i>Pharmacogenetics</i>. 1999;9(5):551-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10591535\">[PubMed 10591535]</a></p>\n<p>3. Castel JM, Cappiello E, Leopaldi D, Latini R. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect. <i>Br J Clin Pharmacol</i>. 1990;30(1):155-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2390428\">[PubMed 2390428]</a></p>\n<p>4. Rythmol (propafenone) [product monograph]. St-Laurent, Quebec, Canada: BGP Pharma Inc; December 2014.</p>\n<p>5. Rythmol (propafenone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9379":"<p><b>Title</b> Lacidipine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Lacidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Grapefruit and grapefruit products should be avoided during lacidipine treatment.</p> \n<p><b>Discussion</b> Lacidipine UK and Korean product labeling states that use with grapefruit juice should be avoided due to the potential for altered lacidipine bioavailability.<sup>1,2</sup> The suspected primary mechanism of this interaction is grapefruit juice inhibition of CYP3A4-mediated intestinal lacidipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Motens (lacidipine) [summary of product characteristics]. Middlesex, United Kingdom: GSK UK; September 2013. </p>\n<p>2. Vaxar (lacidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200511002. Accessed August 19, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9380":"<p><b>Title</b> Dantrolene / Lacidipine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Korean labeling recommends avoiding this combination while UK product labeling does not mention this purported interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lacidipine may enhance the adverse/toxic effect of Dantrolene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Korean product labeling for the dihydropyridine calcium channel blocker lacidipine recommends avoiding use with dantrolene. Lacidipine UK product labeling does not mention the potential interaction. If this combination is used, monitor patient closely for evience of toxicity.</p> \n<p><b>Discussion</b> Two published case reports describe patients who experienced hyperkalemia and reduced cardiac output when intravenous (IV) dantrolene was administered during treatment with the non-dihydropyridine calcium channel blockers diltiazem or verapamil.<sup>1,2</sup> The patient in one of these cases later received IV dantrolene during treatment with the dihydropyridine calcium channel blocker nifedipine without adverse effects.<sup>2</sup> Dantrolene US prescribing information states that IV dantrolene and calcium channel blockers such as verapamil should not be used together.<sup>3</sup> <br><br>The mechanism of this interaction is unclear. While dihydropyridine calcium channel blockers have not been implicated as potential interacting agents, Korean product labeling for the dihydropyridine calcium channel blocker lacidipine recommends avoiding use with dantrolene.<sup>4</sup> Lacidipine UK product labeling does not mention the potential interaction.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yoganathan T, Casthely PA, Lamprou M. Dantrolene-induced hyperkalemia in a patient treated with diltiazem and metoprolol. <i>J Cardiothorac Anesth</i>. 1988;2(3):363-364. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17171874\">[PubMed 17171874]</a></p>\n<p>2. Rubin AS, Zablocki AD. Hyperkalemia, verapamil, and dantrolene. <i>Anesthesiology</i>. 1987;66(2):246-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3813090\">[PubMed 3813090]</a></p>\n<p>3. Dantrium (dantrolene) injection [prescribing information]. Cincinnati, OH: Procter &amp; Gamble Pharmaceuticals; October 2008.</p>\n<p>4. Vaxar (lacidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200511002. Accessed August 19, 2014.</p>\n<p>5. Motens (lacidipine) [summary of product characteristics]. Middlesex, United Kingdom: GSK UK; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9381":"<p><b>Title</b> Lacidipine / Baclofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Baclofen may enhance the hypotensive effect of Lacidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving baclofen for enhanced blood pressure-lowering effects of lacidipine.</p> \n<p><b>Discussion</b> Korean product labeling recommends monitoring patients receiving baclofen for enhanced lacidipine blood pressure-lowering effects.<sup>1</sup> While no data characterizing an interaction between these agents are available, both baclofen and lacidipine have been independently associated with hypotension.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vaxar (lacidipine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200511002. Accessed August 19, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9382":"<p><b>Title</b> Nitrazepam / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Nitrazepam. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 6 healthy volunteers, coadministration of cimetidine (200 mg three times daily and 400 mg at bedtime, beginning 24 hours before nitrazepam dosing) decreased the clearance of nitrazepam (5 to 10 mg single oral dose) by 17% without affecting its maximum serum concentration.<sup>1</sup> The suspected primary mechanism of this interaction is cimetidine inhibition of nitrazepam metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. <i>Clin Pharmacol Ther</i>. 1983;34(2):227-230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6872417\">[PubMed 6872417]</a></p>\n<p>2. Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9383":"<p><b>Title</b> Nitrazepam / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Nitrazepam. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, coadministration of erythromycin (500 mg orally 3 times daily for 6 days) increased the maximum concentration and AUC of nitrazepam (5 mg single oral dose) by 28% and 25%, respectively<sup>1</sup> The suspected primary mechanism of this interaction is erythromycin inhibition of nitrazepam metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Luurila H, Olkkola KT, Neuvonen PJ. Interaction between erythromycin and nitrazepam in healthy volunteers. <i>Pharmacol Toxicol</i>. 1995;76(4):255-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7617555\">[PubMed 7617555]</a></p>\n<p>2. Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9384":"<p><b>Title</b> Amodiaquine / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Efavirenz may enhance the hepatotoxic effect of Amodiaquine. Efavirenz may increase the serum concentration of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of amodiaquine and efavirenz.</p> \n<p><b>Discussion</b> A trial of 5 healthy subjects given amodiaquine/artesunate (AQ/AS) alone and then AQ/ AS combined with efavirenz was stopped early when a subject dropped out due to complaints of nausea, and two subjects developed significant increases in serum hepatic transaminase concentrations 40 days after the final dose.<sup>1</sup> Serological tests ruled out other possible causes for elevated liver function tests. Analysis of the two subjects found that the addition of efavirenz resulted in a 114% to 302% increase in the AQ AUC and a 9% to 24% decrease in the AUC of the active desethylamodioaquine metabolite.<br><br>Due to this possible increase in the risk for hepatotoxicity with the combination, concurrent use of AQ/AS is not recommended.<sup>2,3</sup> The specific mechanism for this potential interaction is not certain, but it has been suggested that inhibition of the CYP2C8-mediated metabolism of AQ by efavirenz may increase AQ concentrations, leading to an increase in the risk for AQ-associated toxicities such as hepatotoxicity.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. <i>Clin Infect Dis</i>. 2007;44(6):889-891. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17304470\">[PubMed 17304470]</a></p>\n<p>2. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. www.who.int/malaria (accessed June 4, 2015).</p>\n<p>3. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9385":"<p><b>Title</b> Mefloquine / Amodiaquine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amodiaquine may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for vision problems may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of visual problems when exposed to this combination.</p> \n<p><b>Discussion</b> A case report describes a 10-year-old who had been receiving amodiaquine/artesunate for empiric treatment of malaria and developed acute, painless, reversible vision loss following 3 doses of mefloquine.<sup>1</sup> Other possible causes for these visual symptoms were reportedly ruled out. This possible interaction has been noted in the WHO malaria treatment guidelines.<sup>2</sup><br><br>The specific mechanism for this reported interaction is uncertain, but both mefloquine and amodiaquine have been independently associated with various vision problems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adjei GO, Adabayeri VM, Annobil SH. Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis. <i>Ghana Med J</i>. 2012;46(3):171-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23661833\">[PubMed 23661833]</a></p>\n<p>2. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. www.who.int/malaria (accessed June 4, 2015).</p>\n<p>3. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9386":"<p><b>Title</b> Amodiaquine / Sulfamethoxazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: The significance of this interaction may be greatest in HIV-infected patiets, in whom this combination should be avoided.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sulfamethoxazole may enhance the neutropenic effect of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of sulfamethoxazole/trimethoprim and amodiaquine in HIV-infected patients when possible due to the possible increased risk for neutropenia. If such combination is unavoidable in the pursuit of prompt therapy, monitor patient response closely, including particular attention for evidence of neutropenia. Although this may of particular concern in HIV-co-infected patients, carefully consider the potential risks and benefits in all patients, and monitor any use of the combination closely.</p> \n<p><b>Discussion</b> The WHO guidelines on malaria treatment caution that HIV-co-infected patients receiving sulfamethoxazole/trimethoprim (SMZ/TMP) may be at greater risk for neutropenia.<sup>1</sup> The degree to which this reflects an interaction or just a baseline risk of amodiaquine is unclear, particularly in HIV-positive patients. Mild or moderately severe neutropenia occurring 14 days after initiation of artesunate/amodiaquine (AS/AQ) was significantly more common in HIV-infected children (n=26) than in HIV-uninfected children (n=134) (45% vs. 6%, respectively).<sup>2</sup><br><br>It is also uncertain whether any interaction is attributable primarily to the sulfamethoxazole or trimethoprim component, or whether it is specific to use of the SMZ/TMP combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. www.who.int/malaria (accessed June 4, 2015).</p>\n<p>2. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. <i>Clin Infect Dis</i>. 2008;46:985-991. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18444813\">[PubMed 18444813]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9387":"<p><b>Title</b> Amodiaquine / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of amodiaquine and trimethoprim is not recommended. This combination may be of even greater risk in HIV-infected patients due to a particular increase in risk for neutropenia.</p> \n<p><b>Discussion</b> According to the artesunate/amodiaquine (AS/AQ) labeling, use with trimethoprim is not recommended due to a risk for trimethoprim inhibition of amodiaquine metabolism.<sup>1</sup> Trimethoprim is an inhibitor of CYP2C8, which has been shown to be at least partially responsible for the metabolismof amodiaquine.<br><br>Additionally, the WHO guidelines on malaria treatment caution that HIV-co-infected patients receiving sulfamethoxazole/trimethoprim (SMZ/TMP) may be at greater risk for neutropenia.<sup>2</sup> The degree to which this reflects an interaction or just a baseline risk of amodiaquine is unclear, particularly in HIV-positive patients. Mild or moderately severe neutropenia occurring 14 days after initiation of AS/AQ was significantly more common in HIV-infected children (n=26) than in HIV-uninfected children (n=134) (45% vs. 6%, respectively).<sup>3</sup><br><br>It is also uncertain whether this possible increase in neutropenia risk is attributable primarily to the sulfamethoxazole or trimethoprim component, or whether it is specific to use of the SMZ/TMP combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p>2. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. www.who.int/malaria (accessed June 4, 2015).</p>\n<p>3. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. <i>Clin Infect Dis</i>. 2008;46:985-991. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18444813\">[PubMed 18444813]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9388":"<p><b>Title</b> Propranolol / Nisoldipine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nisoldipine may increase the serum concentration of Propranolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required beyond the routine blood pressure and heart rate monitoring that accompanies the use of nisoldipine or propranolol alone.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, nisoldipine (20 mg single oral dose) increased the propranolol (40 mg single oral dose) AUC and maximum serum concentration (Cmax) 43% and 68%, respectively.<sup>1</sup> The nisoldipine AUC and Cmax increased 28% and 57%, respectively.<sup>1</sup> The heart rate response to isoproterenol was reduced with the combination of propranolol and nisoldipine compared with propranolol alone.<sup>1</sup> In another study of 8 healthy volunteers, propranolol (160 mg daily for 14 days) was combined with nisoldipine (20 mg daily on days 7 to 14) and pharmacokinetic measurements were evaluated on days 7 and 14.<sup>2</sup> On day 7, the propranolol AUC and Cmax increased 35% and 55%, respectively, and, on day 14, the propranolol AUC and Cmax increased 60% and 55%, respectively.<sup>2</sup> <br><br>In contrast, in a study of 12 healthy volunteers, nisoldipine (10 mg twice daily for 7 days) had no effect on the propranolol (80 mg twice daily for 7 days) AUC or Cmax.<sup>3</sup> No changes were noted in nisoldipine pharmacokinetic parameters.<sup>3</sup> Additionally, the combination of nisoldipine and propranolol has been shown to be safe and effective for the treatment of angina.<sup>4</sup><br><br>The mechanism of this potential interaction is unknown, but changes in hepatic blood flow induced by nisoldipine leading to reduced first pass metabolism of propranolol has been proposed.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Levine MA, Ogilvie RI, Leenen FH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. <i>Clin Pharmacol Ther</i>. 1988;43(1):39-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2826066\">[PubMed 2826066]</a></p>\n<p>2. Elliott HL, Meredith PA, McNally C, Reid JL. The interactions between nisoldipine and two beta-adrenoceptor antagonists-atenolol and propranolol. <i>Br J Clin Pharmacol</i>. 1991;32(3):379-385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777376\">[PubMed 1777376]</a></p>\n<p>3. Shaw-Stiffel TA, Walker SE, Ogilvie RI, Leenen FH. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol. <i>Clin Pharmacol Ther</i>. 1994;55(6):661-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8004882\">[PubMed 8004882]</a></p>\n<p>4. De Caprio L, Papa M, Acanfora D, et al. Acute effects of nisoldipine, propranolol, and their combination in patients with chronic stable angina: a double-blind, randomized, cross-over, placebo-controlled study. <i>J Cardiovasc Pharmacol</i>. 1990;16(2):325-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1697390\">[PubMed 1697390]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9389":"<p><b>Title</b> Amodiaquine / Zidovudine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Zidovudine may enhance the neutropenic effect of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of zidovudine-containing antiretroviral therapy with amodiaquine due to the possible increased risk for neutropenia. If such combination is unavoidable in the pursuit of prompt therapy, monitor patient response closely, including particular attention for evidence of neutropenia.</p> \n<p><b>Discussion</b> The risk for neutropenia in HIV-infected patients receiving artesunate/amodiaquine (AS/AQ) plus sulfamethoxazole/trimethoprim (SMZ/TMP) and antiretroviral therapy (11 of 12 receiving zidovudine) was significantly higher than those receiving AS/AQ and SMX/TMP without ART (75% vs. 26%, respectively).<sup>1</sup><br><br>The WHO guidelines on malaria treatment caution that HIV-co-infected patients receiving zidovudine may be at greater risk for neutropenia.<sup>2</sup> The degree to which this reflects an interaction or just a baseline risk of amodiaquine is unclear, particularly in HIV-positive patients. Mild or moderately severe neutropenia occurring 14 days after initiation of AS/AQ was significantly more common in HIV-infected children (n=26) than in HIV-uninfected children (n=134) (45% vs. 6%, respectively).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. <i>Clin Infect Dis</i>. 2008;46:985-991. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18444813\">[PubMed 18444813]</a></p>\n<p>2. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. Www.who.int/malaria (accessed June 4, 2015).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9390":"<p><b>Title</b> Beta-Blockers / NIFEdipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> NIFEdipine may enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for signs and symptoms of excessive hypotension and heart failure if nifedipine is added to beta-blocker therapy. The immediate-release formulation of nifedipine may be more of a concern than extended-release products.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 15 patients with hypertension and angina, nifedipine (10 mg twice daily) was added to each patient's stable antihypertensive regimen consisting of atenolol (50 mg to 100 mg daily) and a diuretic (drug and dose not stated).<sup>1</sup> Eight patients were also taking prazosin.<sup>1</sup> The addition of nifedipine was well tolerated in most patients, but 1 patient experienced severe hypotension (blood pressure 80/60 mm Hg) and weakness. Atenolol and nifedipine were discontinued and blood pressure returned to normal. The patient's angina returned so his atenolol was resumed (without nifedipine) and his blood pressure remained stable.<sup>1</sup> A case report describes a 47-year-old man who experienced hypotension (systolic blood pressure 60 mm Hg), dizziness, and renal failure after the addition of nifedipine (10 mg three times daily) to his medication regimen containing propranolol (160 mg four times daily).<sup>2</sup> Another case report describes the excessive hypotension, asystolic cardiac arrest, and death of a 38-year-old woman who received labetalol and nifedipine.<sup>3</sup> She was prescribed nifedipine extended release (XL) 90 mg once daily, which was incorrectly crushed and administered via nasogastric tube. The crushed XL tablet allowed for excessive absorption of nifedipine and likely contributed to the patient's fatal outcome.<sup>3</sup> In addition to the excessive hypotensive effects, one report describes 2 patients who developed signs and symptoms of heart failure (dyspnea, edema, jugular venous distention) after the addition of nifedipine (10 mg three times daily) to their beta blocker therapy.<sup>4</sup> The patients had no history of heart failure prior to these episodes and all signs and symptoms of heart failure resolved after nifedipine discontinuation.<sup>4</sup> In contrast, numerous clinical studies have shown the combination of nifedipine and a beta-blocker to be safe and effective for the treatment of angina and/or hypertension.<sup>5,6,7,8,9,10,11,12,13,14</sup><br><br>In a pharmacokinetic study of 8 healthy volunteers, propranolol (titrated up to 20 mg three times daily) increased the nifedipine (10 mg single oral dose) AUC and maximum serum concentration 26% and 57%, respectively.<sup>15</sup> In contrast, in another pharmacokinetic study of 8 healthy volunteers, the administration of metoprolol (100 mg twice daily) or atenolol (100 mg once daily) had no effect on the pharmacokinetics of nifedipine (10 mg three times daily).<sup>16</sup><br><br>The mechanism of the pharmacodynamic interactions is likely the result of additive pharmacologic effects as both nifedipine and beta-blockers possess hypotensive and negative inotropic properties. The mechanism by which propranolol may increase nifedipine exposure is unknown, but may relate to changes in hepatic blood flow and reduced first-pass metabolism.<sup>15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. <i>Br Med J</i>. 1980;281(6253):1462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7437840\">[PubMed 7437840]</a></p>\n<p>2. Staffurth JS, Emery P. Adverse interaction between nifedipine and beta-blockade. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6259):225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6779963\">[PubMed 6779963]</a></p>\n<p>3. Schier JG, Howland MA, Hoffman RS, Nelson LS. Fatality from administration of labetalol and crushed extended-release nifedipine. <i>Ann Pharmacother</i>. 2003;37(10):1420-1423. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519033\">[PubMed 14519033]</a></p>\n<p>4. Anastassiades CJ. Nifedipine and beta-blocker drugs. <i>Br Med J</i>. 1980;281(6250):1251-1252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6107167\">[PubMed 6107167]</a></p>\n<p>5. Ferguson JD, Ormerod O, Lenox-Smith AJ. Bisoprolol alone and in combination with amlodipine or nifedipine in the treatment of chronic stable angina. <i>Int J Clin Pract</i>. 2000;54(6):360-363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11092108\">[PubMed 11092108]</a></p>\n<p>6. Suzuki H, Nakamoto H, Nemoto H, Sugahara S, Okada H. Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine. <i>Hypertens Res</i>. 2000;23(2):159-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10770263\">[PubMed 10770263]</a></p>\n<p>7. Toal CB, Motro M, Baird MG, et al. Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina. <i>Can J Cardiol</i>. 1999;15(10):1103-1109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10523477\">[PubMed 10523477]</a></p>\n<p>8. Nakamoto H, Nemoto H, Sugahara S, Okada H, Suzuki H. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up. <i>Hypertens Res</i>. 1999;22(2):75-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10487322\">[PubMed 10487322]</a></p>\n<p>9. Di Somma S, de Divitiis M, Bertocchi F, et al. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. <i>Cardiologia</i>. 1996;41(7):635-643. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8831181\">[PubMed 8831181]</a></p>\n<p>10. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) study. <i>J Am Coll Cardiol</i>. 1996;27(2):311-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8557899\">[PubMed 8557899]</a></p>\n<p>11. Dargie HJ, Ford I, Fox KM. The Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group. <i>Eur Heart J</i>. 1996;17(1):104-112 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8682116\">[PubMed 8682116]</a></p>\n<p>12. Metcalfe MJ, Jennings K. A cross-over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris. <i>Curr Med Res Opin</i>. 1995;13(5):251-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7555033\">[PubMed 7555033]</a></p>\n<p>13. Dargie HJ, Lynch PG, Krikler DM, Harris L, Krikler S. Nifedipine and propranolol: a beneficial drug interaction. <i>Am J Med</i>. 1981;71(4);676-682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7025625\">[PubMed 7025625]</a></p>\n<p>14. Glasser SP, Friedman R, Talibi T, Smith LK, Weir EK. Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. <i>Am J Cardiol</i>. 1994;73(4):213-218. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8296748\">[PubMed 8296748]</a></p>\n<p>15. Zylber-Katz E, Turetz-Abramovitch M, Koren G, Levy M. Pharmacokinetic interaction between nifedipine and propranolol. <i>Fundam Clin Pharmacol</i>. 1988;2(1):29-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3371839\">[PubMed 3371839]</a></p>\n<p>16. Kendall MJ, Jack DB, Laugher SJ, Lobo J, Rolf Smith S. Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol. <i>Br J Clin Pharmacol</i>. 1984;18(3):331-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487472\">[PubMed 6487472]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9392":"<p><b>Title</b> Artesunate / CYP2A6 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of artesunate with CYP2A6 inhibitors is not recommended in the absence of clinical data supporting such combined use.</p>\n<div>\n <p><b>CYP2A6 Inhibitors Interacting Members</b> Amiodarone, Desipramine, Isoniazid, Ketoconazole (Systemic), Letrozole, Methoxsalen (Systemic), Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Labeling for the artesunate/amodiaquine product cautions that, in the absence of clinical data, coadministration with CYP2A6 inhibitors is not recommended.<sup>1</sup> Specific data concerning this interaction are not available.<br><br>Artesunate is a substrate for CYP2A6, suggesting that concurrent use with an inhibitor of CYP2A6 may lead to impaired artesunate metabolism, a possible increased risk for toxicities and adverse effects, and possibly altered effectiveness due to decreased formation of dihydroartemisinin (the active metabolite that accounts for most or all of clinical artesunate antimalarial activity).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9393":"<p><b>Title</b> Atropine (Ophthalmic) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ophthalmic atropine in combination with monoamine oxidase inhibitors.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Ophthalmic atropine US prescribing information states that use with monoamine oxidase inhibitors is not recommended due to the potential for precipitation of hypertensive crisis.<sup>1</sup> This interaction is expected based on the potential for both agents to increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atropine ophthalmic solution [prescribing information]. Lake forest, IL: Akorn Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9394":"<p><b>Title</b> NiMODipine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of nimodipine and strong CYP3A4 inhibitors. Nimodipine US prescribing information lists this as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Nimodipine US prescribing information states that its use with strong CYP3A4 inhibitors is contraindicated due to the potential for increased nimodipine exposure and systemic effects (eg, hypotension).<sup>1</sup> The suspected mechanism of this interaction is inhibition of CYP3A4-mediated nimodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9395":"<p><b>Title</b> NiMODipine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of nimodipine and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study, nimodipine (60 mg single oral dose) maximum concentration and AUC were lower by 89% and 86%, respectively, in 8 patients receiving strong CYP3A4-inducing medications (phenytoin, phenobarbital, or carbamazepine) than in 8 healthy volunteers.<sup>1</sup><br> <br>The suspected mechanism of this interaction is induction of CYP3A4-mediated nimodipine metabolism. Nimodipine US prescribing information states that its use in combination with strong CYP3A4 inducers should generally be avoided due to the potential for reduced nimodipine exposure and systemic effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. <i>Br J Clin Pharmacol</i>. 1991;32(3):335-340. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777370\">[PubMed 1777370]</a></p>\n<p>2. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9396":"<p><b>Title</b> NiMODipine / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced nimodipine effects in patients receiving moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Nimodipine US prescribing information states that patients receiving nimodipine in combination with moderate CYP3A4 inducers should be monitored for lack of nimodipine effectiveness.<sup>1</sup> <br><br>The suspected mechanism of this interaction is induction of CYP3A4-mediated nimodipine metabolism. The suspected mechanism of this interaction is induction of CYP3A4-mediated nimodipine metabolism. In a clinical study, nimodipine (60 mg single oral dose) maximum concentration and AUC were lower by 89% and 86%, respectively, in 8 patients receiving strong CYP3A4 inducing medications (phenytoin, phenobarbital, or carbamazepine) than in 8 healthy volunteers.<sup>2</sup> While no specific data are available characterizing the impact of moderate or weak CYP3A4 inducers on nimodipine pharmacokinetics, their impact on CYP3A4 function is expected to be lower than that of strong inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p>2. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. <i>Br J Clin Pharmacol</i>. 1991;32(3):335-340. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777370\">[PubMed 1777370]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9397":"<p><b>Title</b> NiMODipine / CYP3A4 Inducers (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced nimodipine effects in patients receiving weak CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Weak) Interacting Members</b> Armodafinil, Artemether, Asunaprevir, CloBAZam, Desvenlafaxine, Dexamethasone (Systemic), Echinacea, Ginkgo Biloba, Glycerol Phenylbutyrate, Lesinurad, Licorice, Nevirapine, OXcarbazepine, Rifabutin, Rufinamide, Telotristat Ethyl, Vemurafenib</p>\n</div> \n<p><b>Discussion</b> Nimodipine US prescribing information states that patients receiving nimodipine in combination with weak CYP3A4 inducers should be monitored for lack of nimodipine effectiveness.<sup>1</sup> <br><br>The suspected mechanism of this interaction is induction of CYP3A4-mediated nimodipine metabolism. In a clinical study, nimodipine (60 mg single oral dose) maximum concentration and AUC were lower by 89% and 86%, respectively, in 8 patients receiving strong CYP3A4 inducing medications (phenytoin, phenobarbital, or carbamazepine) than in 8 healthy volunteers.<sup>2</sup> While no specific data are available characterizing the impact of moderate or weak CYP3A4 inducers on nimodipine pharmacokinetics, their impact on CYP3A4 function is expected to be lower than that of strong inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p>2. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. <i>Br J Clin Pharmacol</i>. 1991;32(3):335-340. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777370\">[PubMed 1777370]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9398":"<p><b>Title</b> NiMODipine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of NiMODipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of nimodipine and St. John's wort.</p> \n<p><b>Discussion</b> Nimodipine US prescribing information states that its use in combination with strong CYP3A4 inducers should generally be avoided due to the potential for reduced nimodipine exposure and systemic effects.<sup>1</sup> St. John's wort is listed as an example of a strong CYP3A4 inhibitor. The suspected mechanism of this interaction is induction of CYP3A4-mediated nimodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9399":"<p><b>Title</b> NiMODipine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nimodipine effects in patients receiving moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Nimodipine US prescribing information states that patients receiving nimodipine in combination with moderate CYP3A4 inhibitors should be monitored for increased nimodipine effects.<sup>1</sup> The suspected mechanism of this interaction is inhibition of CYP3A4-mediated nimodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}